| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Thomas Anderson is Director at ZVRA. Thomas Anderson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $205K at current prices.
Net of sales, the ZVRA filings show accumulation of 20,000 shares.
Thomas Anderson has 6 Form 4 filings on record from August 2023 to June 2026, all as Director at Zevra Therapeutics (ZVRA), 2023–2026.
The 6 reported transactions were 4 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $117K and no sales.
The largest open-market purchase was 10,000 shares of ZVRA at an average $6.81 on July 16, 2024, about $68K. Twelve months later ZVRA was up 88%.